At the end of the latest market close, Dare Bioscience Inc. (DARE) was valued at $1.16. In that particular session, Stock kicked-off at the price of $1.17 while reaching the peak value of $1.18 and lowest value recorded on the day was $1.1498. The stock current value is $1.28.Recently in News on January 9, 2023, Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause. Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause. You can read further details here
Dare Bioscience Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.3000 on 01/25/23, with the lowest value was $0.8300 for the same time period, recorded on 01/03/23.
Dare Bioscience Inc. (DARE) full year performance was -23.68%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Dare Bioscience Inc. shares are logging -32.01% during the 52-week period from high price, and 55.89% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.82 and $1.88.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1245499 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Dare Bioscience Inc. (DARE) recorded performance in the market was 39.76%, having the revenues showcasing 20.82% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 96.28M, as it employees total of 20 workers.
The Analysts eye on Dare Bioscience Inc. (DARE)
During the last month, 0 analysts gave the Dare Bioscience Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.9911, with a change in the price was noted +0.17. In a similar fashion, Dare Bioscience Inc. posted a movement of +15.74% for the period of last 100 days, recording 267,573 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for DARE is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Dare Bioscience Inc. (DARE)
Raw Stochastic average of Dare Bioscience Inc. in the period of last 50 days is set at 89.58%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 89.58%. In the last 20 days, the company’s Stochastic %K was 83.83% and its Stochastic %D was recorded 79.27%.
Considering, the past performance of Dare Bioscience Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 39.76%. Additionally, trading for the stock in the period of the last six months notably improved by 5.45%, alongside a downfall of -23.68% for the period of the last 12 months. The shares increased approximately by -0.85% in the 7-day charts and went down by 34.73% in the period of the last 30 days. Common stock shares were driven by 20.82% during last recorded quarter.